E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
A randomised controlled trial to find out whether tailored pill use is better than standard pill use by seeing which approach leads to more women staying on the pill for at least one year. |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Reproductive physiologi cal processes [G08] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 13.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10030970 |
E.1.2 | Term | Oral contraception |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of the trial is to compare two alternative ways of taking COC to determine which is associated with better continuation rates. Which of the two regimens is associated with the highest proportion of women continuing to take COC at 12 months. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives are to compare, across the two arms of the trial, the proportion of women reporting:
1- adherence
2- user satisfaction with way of taking COC
3- bleeding, both spotting and heavier bleeding
4- other side effects (known or perceived)
5- switching to another way of taing COC
6- switching to another method of contraception
7- pregnancy |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
The substudy will involve in-depth qualitative interviews. This will involve 30 women in the two arms of the study. Particpants will be asked 6 questions on their experience of taking the pill and what if any side effects they may have experienced during the time. |
|
E.3 | Principal inclusion criteria |
Females 18 to 45 years of age inclusive
Requesting COC as future or ongoing method of contraception and for this method to be an apprpriate choice
Willing to be randomised to one of the two groups
Willing to follow protocol for 12 months
Able to provide written consent
Access to the internet, has an email address and willing to complete an online diary regularly, i.e. weekly for up to 12 months after starting the allocated regimen |
|
E.4 | Principal exclusion criteria |
Currently on medication which may influence the efficacy of COC
Any recognised (WHO eligibility criteria 3&4 ) contraindication to COC (UKMEC, 2007)
Unable or unwilling to complete online diary for 12 months
Unable to provide written consent |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary objective of the trial is to coampare two alternative ways of taking COC to determine which is associated with better continuation rates. As measured by the proportion of women continuing to take COC at 12 months. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 11 |
E.8.5 | The trial involves multiple Member States | No |
E.8.5.1 | Number of sites anticipated in the EEA | 11 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | |